利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.017 秒)

    METHODS AND COMPOSITIONS FOR DIAGNOSIS, MONITORING AND DEVELOPMENT OF THERAPEUTICS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR DIAGNOSIS, MONITORING AND DEVELOPMENT OF THERAPEUTICS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE 审中-公开
    用于治疗甲状腺疾病的治疗药物的诊断，监测和开发的方法和组合

    公开(公告)号：US20090305903A1

    公开(公告)日：2009-12-10

    申请号：US12205618

    申请日：2008-09-05

    申请人： Raymond TABIBIAZAR ,  Thomas Quertermous

    发明人： Raymond TABIBIAZAR ,  Thomas Quertermous

    IPC分类号： C40B30/04 ,  C12Q1/68 ,  C40B40/08

    CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition.

    摘要翻译： 提供了与动脉粥样硬化疾病病症中差异表达的基因相对应的多核苷酸序列。 还提供了使用这些序列来检测哺乳动物的基因表达和/或转录谱的方法。 本发明的多核苷酸序列可用于诊断动脉粥样硬化疾病，监测治疗进展程度或疗效或评估动脉粥样硬化疾病的预后，和/或鉴定有效治疗动脉粥样硬化疾病病症的化合物。

    TWO BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    2.
    发明申请
    TWO BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 审中-公开
    两个生物标记物用于诊断和监测甲状旁腺性心脏病

    公开(公告)号：US20080300797A1

    公开(公告)日：2008-12-04

    申请号：US11963673

    申请日：2007-12-21

    申请人： Raymond TABIBIAZAR ,  Evangelos Hytopoulos

    发明人： Raymond TABIBIAZAR ,  Evangelos Hytopoulos

    IPC分类号： G01N33/48

    CPC分类号： G16B40/00 ,  G16B20/00 ,  G16B25/00 ,  Y02A90/24 ,  Y02A90/26

    摘要： The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

    摘要翻译： 本发明鉴定了新鉴定为在动脉粥样硬化中差异表达的两种循环蛋白。 这两种蛋白质的循环水平，特别是作为一组蛋白质，可以将患有急性心肌梗死的患者与具有稳定的劳力性心绞痛的患者以及没有动脉粥样硬化性心血管疾病史的患者区分开来。 这些水平也可以预测心血管事件，确定治疗的有效性，疾病阶段等。 例如，这些标记物可用作开发血管特异性药剂所需的临床事件的替代生物标志物。